Similarly, in vivo analysis has demonstrated that ATV-treated resistant xenograft models had decreased cholesterol levels inducing downregulation of the CAV-1/GLUT-3 axis, abrogating the glucose uptake, and resulting in lower tumor volumes [30]. The gene discussed is CAV1; the disease is neoplasm.